Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer by van Cruijsen, Hester et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
BMC Cancer
Open Access Research article
Tissue micro array analysis of ganglioside N-glycolyl GM3 
expression and signal transducer and activator of transcription 
(STAT)-3 activation in relation to dendritic cell infiltration and 
microvessel density in non-small cell lung cancer
Hester van Cruijsen1, Mariëlle Gallegos Ruiz1, Paul van der Valk2, Tanja D de 
Gruijl1 and Giuseppe Giaccone*1,3
Address: 1Department of Medical Oncology, VU University Medical Center, Boelelaan 1117, 1081 HV Amsterdam, The Netherlands, 2Department 
of Pathology, VU University Medical Center, Boelelaan 1117, 1081 HV Amsterdam, The Netherlands and 3Medical Oncology Branch, CCR, 
National Cancer Institute, NIH, Bethesda, MD 20892-1906, USA
Email: Hester van Cruijsen - h.vancruijsen@vumc.nl; Mariëlle Gallegos Ruiz - mgallegosruiz@vumc.nl; Paul van der 
Valk - pvandervalk@vumc.nl; Tanja D de Gruijl - td.degruijl@vumc.nl; Giuseppe Giaccone* - giacconeg@mail.nih.gov
* Corresponding author    
Abstract
Background: Tumor immune escape and angiogenesis contribute to tumor progression, and
gangliosides and activation of signal transducer and activator of transcription (STAT)-3 are
implicated in these processes. As both are considered as novel therapeutic targets, we assessed the
possible association of ganglioside GM3 expression and STAT3 activation with suppression of
dendritic cell (DC) activation and angiogenesis in non-small cell lung cancer (NSCLC).
Methods: Immunohistochemistry was performed on a tissue array to determine N-glycolyl GM3
(GM3) and phosphorylated STAT3 (pSTAT3) expression in 176 primary NSCLC resections.
Median values of GM3 and pSTAT3 expression were used as cut off. Microvessel density (MVD)
was determined by CD34 staining and morphology. CD1a and CD83 were used to determine
infiltrating immature and mature dendritic cells, respectively.
Results: 94% and 71% of the NSCLC samples expressed GM3 and nuclear pSTAT3, respectively.
Median overall survival was 40.0 months. Both low GM3 expression and high pSTAT3 expression
were associated with a worse survival, which reached near significance for GM3 (P = 0.08).
Microvessel density (MVD), determined by CD34 staining and morphology, was lower in NSCLC
samples with high GM3 expression. CD1a+ cells (immature DCs) were more frequent in NSCLC
tissues as compared to peritumoral lung tissue, while CD83+ cells (mature DCs) were more
frequent in peritumoral lung tissue. CD83+ DCs were less frequent in NSCLC tissues with high
GM3 expression.
Conclusion: GM3 and pSTAT3 are widely expressed in NSCLC. Based on CD83 expression,
GM3, but not pSTAT3, appeared to be involved in tumor-induced DC suppression. pSTAT3
expression was not associated with MVD, while GM3 might play an anti-angiogenic role.
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Background
Lung cancer is the leading cause of cancer-related deaths
worldwide. Non-small cell lung cancer (NSCLC), consist-
ing mainly of adenocarcinoma, squamous cell and large-
cell carcinoma, accounts for almost 80% of lung cancer
cases. Five-year survival rate for NSCLC patients, irrespec-
tive of histological subtype and stage at diagnosis, approx-
imates 15% [1]. Of the 25% who are candidates for
curative surgery at diagnosis (stage I-IIIA), 65% will
relapse within two years. Most patients present with
advanced disease, and despite recent improvements in
systemic combination regimens, advanced NSCLC
patients still have a poor prognosis [2].
To design new and effective therapies in order to improve
the outcome for NSCLC patients, understanding the
tumor biology and the interplay between tumor cells and
their micro-environment is of utmost importance. Some
characteristics of tumor biology, like deregulated expres-
sion of gangliosides and constitutive activation of signal
transducer and activator of transcription (STAT)-3, have
been implicated in tumor-host interactions, i.e. tumor
immune escape and angiogenesis. Tumor immune escape
is established through a wide variety of active mechanisms
employed by tumors to escape or to frustrate immune
responses [3]. and angiogenesis is the formation of new
blood vessels from the existing vasculature [4]. Both proc-
esses are employed by virtually all solid tumors to initiate
and facilitate tumor progression.
Gangliosides are ubiquitous membrane-associated gly-
cosphingolipids containing at least one sialic acid. Besides
regulatory roles in normal physiological processes, gan-
gliosides have been implicated in tumor development
and progression [5]. The composition and production of
gangliosides is altered in many tumour types. N-glycolyl
GM3, a monosialic ganglioside, is not expressed in nor-
mal human tissues [6], but increased levels of N-glycolyl
GM3 were detected in human breast tumors [7]. Ganglio-
sides are also shed in the tumor microenvironment and
eventually circulate in patients' blood [8,9]. These circu-
lating gangliosides are thought to be involved in tumor-
host interactions facilitating metastasis through tumor
immune escape and tumor-associated angiogenesis. GM3
has been described to impair differentiation and function
of both CD34+ and CD14+-precursor derived dendritic
cells (DC) [10,11]), which are the most potent antigen
presenting cells essential for elicitation of an anti-tumor
immune response, but are often hampered in their devel-
opment and function by tumors [12]. In addition, matu-
ration and function of Langerhans cells (i.e. DCs from the
epidermis) were also shown to be inhibited by GM3 [13].
Not all studies, however, could establish such a DC
immune suppressive role of GM3 [14]. Gangliosides can
also modulate tumor-associated angiogenesis. Low GM3
levels relative to another ganglioside GD3 have been dem-
onstrated to stimulate angiogenesis [15,16]. and GM3 was
the only investigated ganglioside found not to increase
endothelial cell responsiveness to the pro-angiogenic fac-
tor, vascular endothelial growth factor (VEGF) [17].
Although these observations suggest an anti-angiogenic
role for GM3, the opposite has also been demonstrated:
GM3 synergistically increased basic fibroblast growth fac-
tor (bFGF, another important pro-angiogenic factor)-
induced proliferation of bovine aortic endothelial cells
[18].
STAT-proteins are important in oncogenic signaling. This
family comprises seven members: STAT1 to 4, STAT5a and
STAT5b, and STAT6 [19]. Normally, STAT proteins trans-
mit cytoplasmic signals from polypeptide cytokines or
growth factors that have receptors with intrinsic or associ-
ated tyrosine-kinase activity, and consequently modulate
the expression of target genes. Constitutive activation of
STAT3 has been implicated in lung cancer development
[20,21]. In addition, STAT3 activation through phosphor-
ylation in tumor cells has been demonstrated to nega-
tively regulate the adaptive immune responses both by
reducing pro-inflammatory cytokine production, and by
production of soluble factors inhibiting DC maturation
[22]. Inhibiting STAT3 in tumor cells resulted in increased
production of pro-inflammatory factors and reversed DC
suppressive effects [22]. STAT3 activation has also been
implicated in angiogenesis: STAT3 is a direct transcription
activator of the VEGF gene and activation of STAT3 leads
to tumor-associated angiogenesis in vivo [23].
More and more evidence is emerging for a relationship
between angiogenesis and tumor-associated immune sup-
pression. Many tumor-derived factors, such as inter-
leukin-6, prostaglandins and VEGF, are implicated in
both processes. In the present study we further set out to
establish a possible role of GM3 expression and STAT3
activation in tumor immune escape and angiogenesis in
NSCLC, since both are considered as novel therapeutic
targets for this tumor type. To this end, we examined
through immunohistochemistry the GM3 and phosphor-
ylated STAT3 (pSTAT3) status of 176 primary NSCLC sec-
tions in a tissue micro array (TMA) and correlated this to
DC infiltration, microvessel density and overall survival.
We found that both GM3 and pSTAT3 are ubiquitously
expressed in NSCLC. pSTAT3 expression could not be
associated with either tumor immune escape or angiogen-
esis. In addition, we did not find evidence for a pro-ang-
iogenic role of GM3, but we did observe an association of
high GM3 expression levels with a decrease in the number
of activated tumor-infiltrating DC in NSCLC patients.BMC Cancer 2009, 9:180 http://www.biomedcentral.com/1471-2407/9/180
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Methods
Patients and NSCLC tissue micro array
We studied 176 NSCLC patients, who underwent a pri-
mary tumor resection at the VU University Medical Center
from 1988 until 2005. From the resected NSCLC material,
tissue micro arrays (TMA) were created (Figure 1A) [24].
In short, paraffin-embedded tumor material was cut into
4 μm-thick sections and placed onto glass slides. Slides
were stained with hematoxylin and eosin and an experi-
enced pathologist verified the presence of tumor cells and
marked the tumor area. 0.6 mm diameter biopsies were
taken from the donor block, two from the tumor and one
from the normal tissue area surrounding the tumor. Biop-
sies from the donor blocks were included in recipient tis-
sue array blocks using a precision tissue array instrument
(Beecher Instruments, Sun Prairie, WI, USA). From this
tissue array block sections were made for immunohisto-
chemistry.
Normal lung tissue, referred to as peritumoral lung tissue,
was only available in 126 cases. As few biopsies mounted
on the glass slide got lost during the procedure of creation
and staining, in some analyses we did not obtain the max-
imum NSCLC samples of 176.
The study was approved by the Medical Ethical Commit-
tee and carried out in accordance with the ethical guide-
lines of our institution concerning informed consent
about the use of patient's material after surgical proce-
dures.
GM3 and pSTAT3 expression Figure 1
GM3 and pSTAT3 expression. (A) Overview of multiple NSCLC sections stained with 14F7 and examples of cytoplasmic, 
nuclear and negative staining of 14F7 in NSCLC. (B) Positive or negative nuclear pSTAT3 expression in NSCLC. Open arrows 
indicate example of nuclear staining; magnifications are indicated. (C) Kaplan-Meier survival analyses for overall survival based 
on GM3 expression or nuclear pSTAT3 expression in early-stage NSCLC patients. Median expression values were used to 
generate dichotomous variables. NSCLC, non-small cell lung cancer.BMC Cancer 2009, 9:180 http://www.biomedcentral.com/1471-2407/9/180
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Immunohistochemistry
TMA sections were deparaffinized and endogenous perox-
idase activity was blocked with 0.3% hydrogen peroxide/
methanol for 30 minutes. TMAs were subjected to none, 1
mM Tris/EDTA- or 10 mM citrate-based antigen-retrieval,
depending on which primary antibody was used. Subse-
quently, slides were incubated with the appropriately
diluted primary antibody at 4°C in a moist chamber.
Bound primary antibodies were visualized using EnVi-
sion-reagents and diaminobenzidine (DAB+) chromogen
(DakoCytomation, Glostrup, Denmark). Slides were
counterstained with haematoxylin. Scoring and quantita-
tion for all stainings were based on the whole biopsy sur-
face (0.28 mm2) and on consensus between two
independent observers.
To determine N-glycolyl GM3 expression in NSCLC tis-
sue, the murine IgG1 anti-GM3 (N-glycolyl) monoclonal
antibody 14F7 was used (kindly provided by Daniel
Alonso, Buenos Aires, Argentina) [7]. Immunostaining
with 14F7 did not require antigen retrieval, and 14F7
(1:1000) was incubated for 18 hours at 4°C. Mean per-
centage 14F7 positive cells of total number of tumor cells
were determined per NSCLC case. In most statistical anal-
yses, median value was used to create dichotomous varia-
bles.
STAT3 activation was determined by staining with a mon-
oclonal antibody against STAT3 phosphorylated at tyro-
sine residue 705 (Clone D3A7; Cell Signaling, Boston,
MA). Pre-treatment involved heating the slides in Tris/
EDTA for 30 minutes. The primary antibody (1:50) was
then incubated overnight at 4°C. NSCLC samples with
nuclear expression of pSTAT3 were designated positive.
Number of positive tumor cells was multiplied by inten-
sity of staining (0, 1, 2, or 3). Dichotomous variables were
generated using median values as cut off.
Immature and mature DC infiltration was determined by
monoclonal antibodies against CD1a (Clone MTB1;
Monosan, Uden, The Netherlands) and CD83 (Clone
1H4b; Monosan, Uden, The Netherlands), respectively
[25]. Both CD1a and CD83 immunostaining required cit-
rate-based antigen retrieval. Both CD1a (1:5) and CD83
antibodies (1:25) were incubated for 1 hour at 4°C. Mean
number of CD1a or CD83 positive cells per NSCLC case
or per corresponding peritumoral lung tissue was calcu-
lated. If any infiltrating immature or mature DC were
present, NSCLC cases were designated positive for imma-
ture or mature DC infiltration.
Microvessel density (MVD) per section was measured
using immunostaining with a CD34-monoclonal anti-
body (Clone QBEnd10; DakoCytomation, Glostrup, Den-
mark), which required citrate-based antigen retrieval and
an one-hour incubation of the primary antibody (1:50) at
4°C. MVD of each NSCLC case was defined as the mean
number of CD34+ vessels per section (0.28 mm2). Since
the sections were small, we did not identify a hot spot to
count the CD34+ vessels, but counted vessels in the entire
section.
Statistics
The statistical analysis between categorical data was done
using the Pearson's Chi-Square test. Student's t-tests were
performed to compare categorical data with continuous
data. Kaplan-Meier plots and log rank analysis were
applied to determine the significance of differences in
overall survival. Values of P ≤ 0.05 (two-tailed) were con-
sidered statistically significant.
Overall survival was the time between diagnosis and the
date of death or the date at which patients were last
known to be alive. For survival analysis, data collection
was locked on 21st of February, 2007.
Results
Patient characteristics
NSCLC samples of 176 patients, who underwent resection
of their primary tumor, were included on the TMAs. A
summary of patient characteristics is listed in Table 1.
Median overall survival of the population was 40.0
months. Low tumor stage and complete resection were
predictive of favourable prognosis (log rank, P = 0.02 and
P  = 0.0009, respectively). Age, gender and histological
subtype were not correlated with overall survival.
Table 1: Patient characteristics
Mean age (years) 64.5
Gender (%)
Male 72
Female 28
Histology (%)
Adenocarcinoma 36
Squamous cell carcinoma 43
Large cell carcinoma 15
Adenosquamous cell carcinoma 3
Broncho-alveolar carcinoma 4
Stage (%)*
I5 1
II 29
III 20
Smoking history (%)
Current 34
Former 39
Non-smoking 2
Unknown 25
* According to American Joint Committee on CancerBMC Cancer 2009, 9:180 http://www.biomedcentral.com/1471-2407/9/180
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GM3 and pSTAT3 expression in NSCLC
GM3 was expressed in almost all NSCLC samples: 94% of
the 165 evaluable NSCLC samples expressed GM3, i.e.
more than 5% of the tumor cells were positive. We
defined positive cells as having cytoplasmic staining. Fur-
thermore, GM3 expression was high: in 52% of all NSCLC
samples, over 90% of the tumor cells were positive for
14F7. In 15% of the cases additional nuclear staining of
14F7 could be detected (Figure 1A). No association could
be established between the different histological subtypes
of NSCLC and GM3 expression, nor between tumor stage
and GM3 expression. Of note, the GM3 expression rate in
peritumoral lung tissue samples was also high, i.e. of 97%
of the peritumoral samples, more than 5% of the lung epi-
thelial cells were positive. However, expression levels were
significantly lower than in NSCLC samples: in only 19%
of all peritumoral lung samples, over 90% of the tumor
cells were positive for 14F7 (as compared to 52% in
NSCLC, peritumoral vs NSCLC, P < 0.001).
pSTAT3 expression in the nucleus was present in 71% of
the 164 evaluable NSCLC samples. Typical nuclear
pSTAT3 immunostaining in NSCLC is shown in Figure 1B.
Although previously reported to be associated with
smaller tumors, limited smoking history and adenocarci-
noma [20], we could detect no such associations between
nuclear pSTAT3 expression and the clinical parameters
tumor stage, histology, and smoking history. Peritumoral
pSTAT3 expression did not differ significantly from
pSTAT3 expression in NSCLC.
Using the median value as cut off, NSCLC patients with
low GM3 expression (median percentage of GM3-positive
cells, 91%) or high pSTAT3 expression (median number
of pSTAT3 positive cells multiplied by intensity of staining
[see Materials and Methods], 110) tended to have a worse
overall survival, although this did not reach statistical sig-
nificance (Figure 1C).
DC infiltration and GM3 or pSTAT3 expression in NSCLC 
tissue
Typical immunostainings of CD1a and CD83 in NSCLC
and peritumoral lung tissue are shown in Figure 2A CD1a+
DC infiltration and GM3 expression status in NSCLC were
not found to be associated (data not shown). Mature
CD83+  DCs, however, were significantly more often
present in NSCLC samples with low GM3 expression as
compared to NSCLC samples with high GM3 expression
(Figure 2B). Presence of either immature or mature DCs
was not associated with nuclear pSTAT3 expression in
NSCLC. In addition, DC numbers were not associated
with tumor stage, histology, or smoking history and we
could not establish any association between the number
of infiltrating CD1a+ or CD83+ DCs and overall survival of
NSCLC patients.
The compartmentalization of DCs in tumoral versus peri-
tumoral tissues was previously associated with differential
DC maturation status in breast and colorectal carcinomas
[25-27]. Since TMAs contain small sections (0.28 mm2),
exact architecture of the NSCLC tissue and the tumor-
associated stroma is often lost. To investigate whether the
(peri-)tumoral localization of DC is correlated with its
maturation status, we therefore compared the presence of
immature (CD1a+) and mature (CD83+) DC in the
NSCLC samples with their incidence in peritumoral lung
sections. Although overall frequencies of both immature
and mature DCs were low, we found an increased number
of immature CD1a+ DCs in NSCLC tissue as compared to
peritumoral lung tissue (Figure 2C). Consistently, we
observed less mature CD83+ DCs in NSCLC tissue as com-
pared to peritumoral lung tissue (Figure 2C), which was in
keeping with a previously observed compartmentaliza-
tion according to DC maturation status [25-27].
Microvessel density and GM3 or pSTAT3 expression in 
NSCLC tissue
MVD was defined as the mean number of CD34+ vessels
per section of one NSCLC sample (Figure 3A). MVD in
NSCLC was not associated with tumor stage and smoking
history. Conflicting reports have been made about the
association between MVD and histology [28-30]. We
found a significantly higher MVD in adenocarcinoma as
compared to squamous cell carcinoma (mean values per
NSCLC case [SD]: adenocarcinoma 32.2 [26.2]; squa-
mous cell carcinoma 22.6 [11.4], P = 0.02). MVD was not
found to be associated with overall survival of NSCLC
patients.
NSCLC samples with low GM3 expression had a slightly,
but significantly, higher MVD as compared to high GM3-
expressing NSCLC samples (Figure 3B), while MVD was
not significantly different between NSCLC with low or
high nuclear pSTAT3 expression (Figure 3B).
Discussion
Our studies show that both GM3 and pSTAT3 are widely
expressed in NSCLC and that GM3 expression is associ-
ated with a favourable patient survival (P = 0.08). To date,
no reports have been made about the prognostic value of
GM3 expression, while pSTAT3 has previously been dem-
onstrated not to be associated with survival in NSCLC
patients [20,31]. In our patient population, we found a
trend for an association between high pSTAT3 expression
in NSCLC and worse prognosis, although this did not
reach significance (P = 0.29).
In literature contradictory reports have been made about
the anti-angiogenic or pro-angiogenic potential of GM3
[15-17]. We found no evidence for a pro-angiogenic role,
but rather the opposite, since GM3 expressing tumorsBMC Cancer 2009, 9:180 http://www.biomedcentral.com/1471-2407/9/180
Page 6 of 9
(page number not for citation purposes)
CD1a and CD83 expression Figure 2
CD1a and CD83 expression. (A) CD1a and CD83 immunostaining in both NSCLC tissues and peritumoral lung tissues. 
Magnifications are indicated. (B) Mature (i.e. CD83+) DC infiltration in NSCLC with low (below median) or high (above 
median) GM3 or pSTAT3 expression. (C) Compartmentalization of immature (CD1a+) and mature (CD83+) DCs as deter-
mined by their infiltration in peritumoral lung tissue or NSCLC tissue. NSCLC, non-small cell lung cancer.BMC Cancer 2009, 9:180 http://www.biomedcentral.com/1471-2407/9/180
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were observed to have a slightly lower MVD. Gangliosides
are biosynthesized by sequential enzymatic modifications
by sialyltransferases; GM3 can be converted into GD3 by
alpha2,8-sialyltransferase [5]. As low GM3 levels relative
to GD3 has been implicated in angiogenesis [15], GD3
rather than GM3 may be the active pro-angiogenic factor.
The next issue to be addressed should therefore be
whether alpha2,8-sialyltransferase is expressed in the
NSCLC cases with low GM3 expression and whether this
coincides with high GD3 expression. GD3 in turn may
then be correlated to high MVD in contrast to GM3. Fur-
ther functional studies are clearly needed to confirm the
distinct roles of GM3 and GD3 in angiogenesis.
pSTAT3 expression has been implicated in tumoral VEGF
production and angiogenesis [23]. We could not establish
a correlation between MVD and nuclear pSTAT3 expres-
sion in NSCLC. However, since the correlation between
VEGF and MVD in NSCLC remains controversial [30], the
lack of the correlation between pSTAT3 expression and
MVD may not be unexpected. We did not observe a differ-
ence in nuclear pSTAT3 expression between peritumoral
and NSCLC tissue. The lack of this difference might result
from the production of cytokines and growth factors (like
interleukin-6 and VEGF) by tumor cells. These factors
might condition the surrounding cells, resulting in trans-
location of activated pSTAT3 to the nucleus in peritu-
moral non-malignant tissues.
Although the frequencies of both CD1a- and CD83-posi-
tive cells were low, we observed an inverse correlation
between GM3 expression and infiltrating mature DCs, in
keeping with previous reports, which showed that GM3
inhibited DC differentiation, maturation and migration
[10,11,13]. GM3-induced inhibition of DC maturation
and migration may have led to less mature DCs infiltrat-
ing the tumoral tissue, and consequently, may have con-
tributed to the observed compartmentalization of DCs
according to their maturation status: consistently, we
observed cells expressing CD1a, which is generally
believed to be a marker of immature DCs and to be down-
regulated upon maturation, more frequently in NSCLC
tissue as compared to the corresponding peritumoral lung
tissue. In addition, we observed cells positive for CD83, a
DC maturation marker, more frequently in the peritu-
moral lung tissue as compared to the NSCLC sections.
Although pSTAT3 expression in tumor cells was reported
to be associated with production of DC suppressive
cytokines [22], DCs of any maturation status were not dif-
ferentially infiltrated in NSCLC samples with high
pSTAT3 expression as compared to NSCLC samples with
low pSTAT3 expression.
Although some reports have suggested that infiltrating
mature DCs predict a favourable prognosis in NSCLC
[32,33], we could not establish a correlation between high
numbers of mature tumor-infiltrating DCs and patient
survival. The general paucity of infiltrating DCs in the rel-
atively small NSCLC sections examined on the TMAs
might explain the observed lack of correlation between
DC infiltration and patient survival. More data have been
published about the prognostic significance of MVD in
NSCLC, and although many reports suggest that higher
MVD predicts an adverse prognosis, the exact prognostic
value of MVD remains unclear [30,32]. We could not
establish any correlation between MVD in NSCLC tissue
and patient survival. Differences in technical procedures
might make our results on MVD hard to compare with
published data. Since only small NSCLC sections (0.28
mm2) were mounted on the TMA glass slides, structure of
the tumor-microenvironment might have been lost. Scor-
ing microvessels might be underestimated in these small
sections, especially when considered that MVD is nor-
mally evaluated in the most intense vascularization areas
of the tumor stroma [32,34]. Although TMAs are suitable
Microvessel density Figure 3
Microvessel density. (A) CD34 immunostaining of vascula-
ture in NSCLC to determine microvessel density. Magnifica-
tion is indicated. (B) Microvessel density (MVD) according to 
low (i.e. below median) or high (i.e. above median) GM3 
expression or pSTAT3 expression in NSCLC samples. Mean 
MVD values and SD are shown. NSCLC, non-small cell lung 
cancer.BMC Cancer 2009, 9:180 http://www.biomedcentral.com/1471-2407/9/180
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for studying tumor cell characteristics, they may not be
applicable when studying tumor-associated angiogenesis.
On the other hand, one could argue that TMAs with a
fixed size might be more appropriate to score MVD, since
scoring MVD in the most intense vascularization area of
the tumor stroma is susceptible to investigator's bias.
Our observations of comparable levels of pSTAT3
between healthy and tumor tissues and a lack of correla-
tion with MVD or mature DC infiltration do not support
the implementation of STAT3 inhibitors as anti-ang-
iogenic or immunostimulatory therapeutics in NSCLC. In
contrast, GM3 was expressed at significantly higher levels
in NSCLC than peritumoral lung tissues and was associ-
ated with tumor-related DC suppression, making this an
attractive target for anti-cancer therapies. Approaches to
target gangliosides are currently in early clinical develop-
ment. Many studies focus on monoclonal antibodies
including antibodies against N-glycolyl-containing gan-
gliosides (i.e., 1E10) and on vaccine-based strategies [35-
38]. Although induced immune responses have been
reported, data on clinical efficacy are still lacking. The
more specific murine monoclonal antibody 14F7, which
we used in this study and recognizes N-glycolyl GM3, has
entered clinical development [39]. Further studies are
awaited to establish the clinical efficacy of humanized
14F7. Our present data suggest that side studies monitor-
ing the immune status could be of additional value to
define the role of GM3 in tumor immune escape, e.g.
through DC suppression.
Conclusion
Our immunohistochemical TMA studies show that GM3
and pSTAT3 are widely expressed in NSCLC. pSTAT3
expression could not be associated with either DC-based
tumor immune escape or angiogenesis, negating its sug-
gested role as a 'master-switch' in these tumorigenic proc-
esses, at least for stage I-III NSCLC. In addition, we did not
find evidence for a pro-angiogenic role of GM3. We could,
however, confirm a possible involvement of GM3 in
tumor-induced DC suppression in NSCLC patients. Its
high tumor-specific expression makes GM3 a possible
candidate for tumor targeting. Our findings suggest that it
might be worthwhile to also monitor any angiogenic and
immune effects of these therapeutic strategies that are cur-
rently under clinical development.
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